The Independent Review (PBS) was established as part of Australia’s implementation of the pharmaceutical provisions of the Australia-United States Free Trade Agreement (AUSFTA).
From 1 January 2005, independent review has been available to any applicant whose submission to the Pharmaceutical Benefits Advisory Committee (PBAC) has not resulted in a recommendation to list the drug on the Pharmaceutical Benefits Scheme (PBS). From the July 2006 meeting, independent review is also available where the PBAC has declined to recommend an extension of the listing of an already listed drug. Further information on the eligibility requirements for independent review is contained in Information for Applicants Seeking Review (PBS) (PDF 31 KB)
The Independent Review (PBS) is managed by a convenor who is responsible for ensuring the efficient conduct of each review, including the selection of a reviewer with appropriate skills and expertise.
Administrative instructions and procedural guidelines for the conduct of the Independent Review (PBS) may be found at the following links:
Page currency, Latest update: 27 July, 2006